A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF)
Authors' conclusion
CI administration of 1.25-2.5 g q8h ceftazidime-avibactam may allow prompt attainment and maintenance of optimal joint PK/PD targets during high-intensity CVVHDF.
Study context
- Population
- Critically ill patients with difficult-to-treat resistant Gram-negative (DTR-GN) infections undergoing CVVHDF
- Participants
- 8 patients
- Outcome
- PK/PD profile of CI ceftazidime-avibactam (steady-state free concentrations, total clearance, joint PK/PD target attainment: ceftazidime fCss/MIC≥4 and avibactam fCss/CT > 1)
- Follow-up
- Steady-state
Main finding
As reported in the abstract
- Avibactam median fCss, mg/L (20.7-25.8 mg/L)
- 24.8
- Ceftazidime median CLtot, L/h (2.05-2.96 L/h)
- 2.39
- Avibactam median CLtot, L/h (2.12-2.98 L/h)
- 2.56
- Median CVVHDF dose, mL/h/kg (35.9-40.0 mL/kg/h)
- 38.6
- Correlation of ceftazidime CLtot with CVVHDF dose (p = 0.03)
- r = 0.53
- Correlation of avibactam CLtot with CVVHDF dose (p = 0.006)
- r = 0.64
Observational data: associations, not effects.
Original publication
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF). J Crit Care. Published 12 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →